- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03343782
Outcomes of Expanded Autologous Bone Marrow-derived Mesenchymal Stem Cells Therapy in Type II Diabetes (ASD2)
June 14, 2021 updated by: Vinmec Research Institute of Stem Cell and Gene Technology
Outcomes of Expanded Autologous Bone Marrow-derived Mesenchymal Stem Cells Therapy in Type 2 Diabetes
The purpose of this study is to evaluate the safety and effectiveness of autologous bone marrow-derived mesenchymal stem cells transplantation in the treatment of type 2 diabetes mellitus
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Bone marrow-derived mesenchymal stem cells have the immunosuppressive effect and secrete a variety of cytokines, improve the microenvironment of diabetic patients, targeting insulin resistance tissue, ameliorate the metabolic disorder of islet damage, protect and regeneration of the islet beta cells; reduce high blood sugar.The purpose of this study is to evaluate the safety and effectiveness of autologous bone marrow-derived mesenchymal stem cells transplantation in treatment 30 patients with type 2 diabetes mellitus at Vinmec International Hospital, Hanoi, Vietnam
Study Type
Interventional
Enrollment (Actual)
30
Phase
- Phase 2
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Hanoi, Vietnam, 10000
- Vinmec Research Institute of Stem Cell and Gene Technology
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Males and females from 18 years and above.
- Hemoglobin A1c (HbA1c) is ranged from 7.5% to 9% at baseline.
- Type 2 diabetes duration 5 years or more.
- Before the screening, joint or combined with insulin, oral medications to treat more than 3 months.
- Who signed the informed consent form.
Exclusion Criteria:
- Type 1 diabetes.
- Chronic disease or severe disease, including cancer, severe heart disease, kidney disease, liver disease, etc.
- According to the medical doctor's judgement, may endanger the safety of the subjects
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Stem cell transplantation
Intervention: 30 patients will be transplanted autologous bone marrow-derived mesenchymal stem cells and undergoing 2 treatment with 6 months interval
|
Collect bone marrow from lilac crest using local anaesthetic and syringe collection.
Mesenchymal stem cell will be isolated, expanded and characterized in vitro under the GMP- grade procedure
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Insulin dose
Time Frame: up to the 12-month period following treatment
|
Reduction of insulin dose requirement by ≥50% in both groups
|
up to the 12-month period following treatment
|
Adverse events
Time Frame: up to the 12-month period following treatment
|
Number of adverse events in both groups
|
up to the 12-month period following treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Hemoglobin A1c (HbA1c) level
Time Frame: up to the 12-month period following treatment
|
Improvement of HbA1c level as compared to baseline between two groups
|
up to the 12-month period following treatment
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
November 1, 2017
Primary Completion (Actual)
August 1, 2019
Study Completion (Actual)
August 1, 2019
Study Registration Dates
First Submitted
November 12, 2017
First Submitted That Met QC Criteria
November 12, 2017
First Posted (Actual)
November 17, 2017
Study Record Updates
Last Update Posted (Actual)
June 18, 2021
Last Update Submitted That Met QC Criteria
June 14, 2021
Last Verified
June 1, 2021
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- VinmecRISCGT70
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Type 2 Diabetes Mellitus
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
Mannkind CorporationTerminatedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
Griffin HospitalCalifornia Walnut CommissionCompletedDIABETES MELLITUS TYPE 2United States
-
RWTH Aachen UniversityBoehringer IngelheimCompletedDiabetes Mellitus Type 2 (T2DM)Germany
-
Scripps Whittier Diabetes InstituteSan Diego State UniversityCompletedType 2 Diabetes Mellitus (T2DM)United States
-
AstraZenecaRecruiting
-
Daewoong Pharmaceutical Co. LTD.Not yet recruitingT2DM (Type 2 Diabetes Mellitus)
-
Zhongda HospitalRecruitingType 2 Diabetes Mellitus (T2DM)China
-
Newsoara Biopharma Co., Ltd.RecruitingT2DM (Type 2 Diabetes Mellitus)China
-
Shanghai Golden Leaf MedTec Co. LtdActive, not recruitingType 2 Diabetes Mellitus (T2DM)China
Clinical Trials on Expanded autologous bone marrow-derived mesenchymal stem cell
-
TCA Cellular TherapySuspendedSpinal Cord InjuryUnited States
-
Hadassah Medical OrganizationCompletedMultiple Sclerosis
-
Leiden University Medical CenterCompleted
-
Pharmicell Co., Ltd.RecruitingErectile DysfunctionKorea, Republic of
-
Pharmicell Co., Ltd.RecruitingAlcoholic CirrhosisKorea, Republic of
-
Pharmicell Co., Ltd.Withdrawn
-
Hanyang University Seoul HospitalMinistry of Health & Welfare, Korea; Corestem, Inc.RecruitingSystemic Lupus ErythematosusKorea, Republic of
-
Celal Bayar UniversityThe Scientific and Technological Research Council of Turkey; Acıbadem LabcellCompletedSkin Diseases | Immune System Diseases | Autoimmune Diseases | UrticariaTurkey
-
BioCardia, Inc.Enrolling by invitationHeart Failure, SystolicUnited States
-
National University of MalaysiaCytopeutics Sdn. Bhd.UnknownMiddle Cerebral Artery InfarctionMalaysia